Lysando's Advisory Board

A group of accomplished experts from different fields. Each member brings unique knowledge and experience, together guiding our journey.



Dr. Wilaiporn Chetanachan



Dr. Chetanachan is an innovation expert with a strong track record in driving technological advancements. Her expertise in fostering innovation and technology development greatly enriches our advisory board.



Dr. Thomas Kahn

Deutsche Bank

Dr. Kahn, a member of the team of the 2008 Nobel laureate Harald zur Hausen (German Cancer Research Center), brings over three decades of diverse finance experience across biotech, pharmaceuticals, and healthcare sectors, including a notable tenure at Deutsche Bank AG. His involvement in 200+transactions deepens the expertise of our advisory board.



Dr. Stefan Miller Lysando Co-Founder

Dr. Miller, our Co-Founder, brings extensive expertise as a Consultant and Scientific Advisor, with a rich background as CSO or CEO in biotech firms. His focus on company building, strategic development, and technology/product advancement, particularly in intellectual property strategy, shapes our advisory board with invaluable insights.



Prof. Dr. Daniel C. Nelson

WINIVERSITY OF

MARYLAND

Prof. Nelson's extensive academic journey, specializing in antimicrobial discovery through innovative bacteriophagederived enzymes, enriches our advisory board with profound expertise in combating multidrug-resistant bacteria and pioneering next-generation antimicrobial therapeutics.



Jorge Cortell



Mr. Cortell, Senior Advisor at Harvard Innovation Labs and Strategic VC Advisor at Cross Ocean Fund, is a trailblazer in healthcare technology and entrepreneurship. With a diverse background founding startups and pioneering innovations in AI and precision medicine, his expertise enriches our advisory board's strategic insights in healthcare innovation.



Dr. Holger Zimmermann



Dr. Zimmermann's accomplished journey from research to executive leadership at AiCuris and Bayer Health Care brings extensive expertise in biomedical research to our advisory board. His remarkable contributions to scientific publications, patents, and leadership roles offer invaluable insights into research, development, and strategic governance.

